In this study, we analyze clinicopathologic significance of genes that frequently mutated in myeloid neoplasm patients. We identified great heterogeneity of pathogenic/deleterious genetic variation in
KRAS, NRAS and BRAF are kinases involved in the RAS-RAF-MAPK signaling pathway and also potential tumor-driven genes. Patients with KRAS/NRAS/BRAF mutations are resistant to anti-EGFR monoclonal antib
